永安药业董事长解除留置恢复履职

Core Points - The actual controller and chairman of Yong'an Pharmaceutical, Chen Yong, has had his detention measures lifted after approximately four months [2] - Yong'an Pharmaceutical is a leading player in the taurine industry, holding around 50% of the global market share and exporting products to major companies like Nestlé and Coca-Cola [2] - In the first half of 2025, Yong'an Pharmaceutical reported revenue of 367.4 million yuan, a year-on-year decline of 13.72%, and a net profit of 12.5 million yuan, down 76.19% compared to the previous year [2] Company Operations - Chen Yong is now able to resume his duties as chairman, and the company's production and operational status is reported to be normal [2] - Chen Zidi will no longer act as the interim chairman [2] - The decline in performance is attributed to a sluggish market, affecting both the sales volume and price of taurine products [2] Competitive Advantages - Yong'an Pharmaceutical claims to have unique proprietary processes for its main product, taurine, along with multiple patents that provide competitive advantages in price, quality, and brand [2] - The management has indicated plans to deepen core technology research and continuously enhance core competitiveness [2]